PerkinElmer, Waltham, Mass, will distribute a diagnostic test for preeclampsia from Shuwen Biotech, Deqing, China, in more than 100 countries around the world, accounting for more than 120 million pregnancies annually.
Petra Furu, PhD, PerkinElmer.
Shuwen’s preeclampsia detection kit is a highly accurate, urine-based, noninvasive point-of-care test, meaning no specialized instrumentation or equipment is needed. The test is cost-effective, produces a result in less than 3 minutes, and is currently available for sale in a number of markets. Clinical testing has shown the test to be more than 95% accurate in diagnosing preeclampsia in women who are admitted to hospitals, regardless of reason for admission.
“PerkinElmer is committed to improving the lives of pregnant women and children globally, and this relationship helps us leverage our strong scientific and commercial network to offer Shuwen’s innovative product to more women in need all over the world,” says Petra Furu, PhD, general manager for reproductive health at PerkinElmer. “There is a global need for advanced diagnostic solutions, and we believe this point-of-care test will help address this need with respect to preeclampsia.”
For more information, visit PerkinElmer and Shuwen Biotech.
